Egalet Reports Positive Outcome of First Phase of Category 1 Abuse Deterrence Studies for Egalet-001

Egalet Reports Positive Outcome of First Phase of Category 1 Abuse Deterrence
Studies for Egalet-001

Study Showed Egalet-001, Extended-Release, Oral Morphine, Resistant to Common
Methods of Physical Manipulation

WAYNE, Pa., March 31, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation
(Nasdaq:EGLT) ("Egalet") today announced positive results of the first phase
of the category 1 abuse deterrence studies for Egalet-001, an abuse-deterrent,
extended-release, oral morphine product in development for the treatment of
moderate to severe chronic pain. The product uses Egalet's proprietary
technology which is specifically designed to deter abuse by physical and
chemical manipulation while also providing the ability to tailor the release
of the active pharmaceutical ingredient (API).

Egalet is conducting studies to evaluate Egalet-001's abuse-deterrent
properties in accordance with the draft FDA Guidance titled "Abuse-Deterrent
Opioids - Evaluation and Labeling." The first phase of the category 1 in vitro
studies tested Egalet-001's ability to resist a broad range of common methods
of physical manipulation, including crushing, cutting or grinding by using
readily available items such as spoons, knives or coffee grinders for the
purpose of abuse.

The study results demonstrate that Egalet-001 resists the common forms of
physical manipulation as compared to MS ContinĀ® (morphine sulfate
controlled-release) ("MS Contin"). An independent laboratory tested a number
of household tools (electrical and non-electrical) in an effort to reduce the
particle size for purposes of abuse. These results confirm tests previously
conducted in Egalet's laboratory that showed Egalet-001's strong
abuse-deterrence features.

"The results from the first phase of our abuse deterrence studies demonstrated
that Egalet-001 resists common methods of abuse and manipulation of oral
morphine showing an improvement over the treatment options available on the
market today," said Bob Radie, Egalet's president and chief executive officer.
"We are now moving on to the next phase of our abuse deterrence studies and
remain optimistic that Egalet-001 will demonstrate its potential as an
abuse-deterrent, extended-release oral morphine. This is an important
milestone since individuals with moderate to severe chronic pain remain in
need of effective medicines that are safe and abuse-deterrent."

While the first phase of the category 1 abuse deterrence study looked at the
ability to physically manipulate Egalet-001, the second phase will test the
capacity to extract the active pharmaceutical ingredient (API) from the matrix
using common household solvents. Egalet plans to initiate category 2 and 3
abuse deterrence studies for Egalet-001 in the second quarter of 2014.In
parallel, Egalet is conducting pivotal bioequivalence studies of Egalet-001 to
compare Egalet-001 to MS Contin.

About Egalet-001

Egalet's lead product candidate, Egalet-001, is an abuse-deterrent,
extended-release, oral morphine formulation in development for the treatment
of moderate to severe pain. There are currently no commercially available
abuse-deterrent formulations of morphine, and Egalet-001, if approved, could
fill a significant unmet need in the marketplace. The Company developed
Egalet-001 using Egalet's proprietary, abuse-deterrent, one-component delivery
system to address common methods of abuse, such as crushing in order to
swallow, snort or smoke, or dissolving in order to inject, with an emphasis on
the most common method of abuse of morphine-based products, which is abuse by
injection. Egalet completed Phase1 clinical trials of Egalet-001 and recently
announced the initiation of pivotal trials to establish the bioequivalence of
Egalet-001 to MS Contin, a currently approved oral morphine formulation, in
the first quarter of 2014. Egalet plans to submit an NDA for Egalet-001 in the
fourth quarter of 2014.

About Egalet Technology

In an effort to address the growing problem of prescription drug abuse, Egalet
created two novel, abuse-deterrent technologies with differentiated
abuse-deterrent features that allow for the development of oral pharmaceutical
products and the ability to control the release profile of the active
pharmaceutical ingredient.The Egalet one-component system, which is used for
EG-001 our abuse-deterrent morphine program, has been designed to resist
common methods of abuse and specifically abuse by injection, the leading
method of abuse for morphine. Egalet's two-component system is used to produce
tablets, such as Egalet-002, designed to address common methods of abuse, such
as crushing in order to swallow, snort or smoke, or dissolving in order to
inject while also offering a greater flexibility and control of API release.
In addition, our two-component system offers the ability to develop
combination products with the combination of API's with similar release
profiles or different release profiles.

Egalet has employed its proprietary technology platform to develop a pipeline
of clinical-stage, opioid-based product candidates in tablet form that are
specifically designed to deter abuse by physical and chemical manipulation
while also providing the ability to tailor the release of the API. While
Egalet's lead product candidates are abuse-deterrent, extended-release, oral
formulations of commonly prescribed opioids, the Egalet technology can be
applied broadly across different classes of pharmaceutical products and can be
used to develop combination products that include multiple APIs with similar
or different release profiles.

About Egalet

Egalet Corporation is a specialty pharmaceutical company developing and
planning to commercialize proprietary, abuse-deterrent oral products for the
treatment of pain and other indications. Egalet has created two distinct drug
delivery systems, each with novel abuse-deterrent features and the ability to
control the release profile of the active pharmaceutical ingredient. Using its
proprietary platform, Egalet has developed a pipeline of clinical-stage,
opioid-based product candidates in tablet form that are specifically designed
to deter abuse by physical and chemical manipulation, while also providing
tailored release of the active pharmaceutical ingredient. Its lead product
candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine
formulation in development for the treatment of moderate to severe chronic
pain. There are currently no commercially available abuse-deterrent
formulations of morphine, and if approved, Egalet believes that Egalet-001
would fill a significant unmet need in the marketplace. Its second product
candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone
formulation in development for the treatment of moderate to severe chronic
pain. The Egalet technology can be applied broadly across different classes of
pharmaceutical products and can be used to develop combination products that
include multiple APIs with similar or different release profiles. Visit
www.egalet.com for more information.

Safe Harbor

Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are based on
management's current expectations, and are subject to known and unknown
uncertainties and risks.Actual results could differ materially from those
discussed due to a number of factors, including, but not limited to: the
success of our clinical trials; our ability to obtain regulatory approval of
our product candidates; competitive factors; general market conditions; and
other risks factors described in Egalet's filings with the United States
Securities and Exchange Commission. Egalet assumes no obligation to update or
revise any forward-looking-statements contained in this press release whether
as a result of new information or future events, except as may be required by
law.

CONTACT: E. Blair Clark-Schoeb
         Tel: 917-432-9275
         Email: blair@biotechcomm.com

Egalet Corporation Logo
 
Press spacebar to pause and continue. Press esc to stop.